
Addex Therapeutics reported a net loss of CHF6.7M for 2025, compared to a net profit of CHF7.1M in 2024, with basic and diluted loss per share at CHF 0.06. Cash position was CHF1.6M.
Bullish
Addex Therapeutics advanced its GABAB PAM chronic cough candidate, regained rights to a Phase 2 mGlu2 PAM asset, and secured a Sinntaxis collaboration and Stalicla investment for neurological disorders.
Bearish
Addex Therapeutics reported a CHF6.7M net loss for 2025, a significant decline from 2024 profit, alongside a CHF1.7M decrease in cash and increased losses from associates.